Last Updated on: 22nd November 2023, 04:10 am
A pioneering AI-powered cancer detection system is set to be unveiled by British GP Dr Bea Bakshi at the American Society of Clinical Oncology (ASCO) conference in Chicago. Dr Bakshi, the co-founder and CEO of C the Signs, will present a groundbreaking study showcasing how this innovative technology has revolutionized early cancer diagnosis, leading to increased survival rates.
The study, involving 118,677 patients, highlights the effectiveness of the C the Signs system in real-world settings. The results demonstrate the system’s high sensitivity in detecting cancer during risk assessments. Moreover, the technology showcases its accuracy in identifying the origin of the cancer, assisting doctors in triaging patients to appropriate treatment departments.
Dr Bakshi expressed her excitement over the study’s outcomes, emphasizing that the system’s accuracy and effectiveness will continue to improve as it is further utilized. She stated, “We are creating a future where every patient can survive cancer using this AI prediction technology. This is the most intelligent way to beat cancer.”
Among the patients risk-assessed by C the Signs, 7,295 were diagnosed with cancer. The system successfully identified 7,056 patients as at risk, yielding a sensitivity rate of 96.7% for cancer detection. With a negative predictive value of 97.2%, C the Signs demonstrates its ability to accurately identify cancer cases. Moreover, the system correctly determined the cancer origins in 85.6% of the patients diagnosed with cancer following risk assessments.
C the Signs is already being utilized by over 1,000 primary care practices and 15,000 healthcare professionals in the UK. The technology has recently been launched in the US, with Dr Bakshi and her team actively establishing partnerships with US health systems.
The presentation of this study aligns with the Cancer Moonshot initiative launched by the White House and President Biden. The next phase, known as CancerX, is a public-private partnership aimed at reducing cancer mortality. C the Signs, alongside other prominent organizations, has been announced as a founding member of CancerX.
Dr Bakshi believes that the C the Signs technology will play a crucial role in achieving the ambitious goal of reducing cancer deaths by 50% by 2040, as outlined by the CancerX partnership. The collaboration aims to harness digital innovation to advance cancer prediction and detection, ensuring a significant impact on the lives of individuals affected by cancer.
The unveiling of this groundbreaking study at ASCO signifies a major advancement in cancer research and treatment. Through collaborative efforts and technological innovation, the CancerX partnership seeks to drive progress in the fight against cancer and alleviate its global burden.
Dr Bakshi is scheduled to present the results of the C the Signs study at the McCormick Place Convention Center in Chicago on Monday, June 5th. Further details about the study can be found at the following link: https://meetings.asco.org/abstracts-presentations/219520.
